MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2017 International Congress

    The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

    I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effect of mirtazapine, a clinically-available anti-depressant, on psychosis and dyskinesia in Parkinson’s disease (PD). Background: Psychosis and dyskinesia cause significant morbidity…
  • 2017 International Congress

    SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias

    A.-A. Roussakis, D. Towey, P. Piccini (London, United Kingdom)

    Objective: This study was designed to explore in Parkinson’s disease (PD) the role of dopamine transporter (DAT)-specific single photon emission computed tomography (SPECT) imaging as a…
  • 2017 International Congress

    Wearable motion quantification and electronic diaries for long-term monitoring of Parkinson’s disease

    A. Hadley, E. Mendoza, N. Mennucci, C. Zimmerman, J. Giuffrida, Z. Mari, M. Burack, I. Itin, F. Revilla, D. Heldman (Cleveland, OH, USA)

    Objective: To clinically assess wearable motion sensors for measuring tremor, dyskinesia, slowness, and mobility and an electronic diary for Parkinson’s disease (PD) Background: A patient…
  • 2017 International Congress

    The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

    C. Kwan, I. Frouni, V. Nafade, D. Gagnon, M.-J. Wallman, L. Sid-Otmane, M. Parent, A. Parent, C. Rouillard, H. Adjia, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effectiveness of highly-selective metabotropic glutamate 2 receptor (mGluR2) activation at alleviating and preventing the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Chronic…
  • 2017 International Congress

    Anosognosia for Levododopa-induced Dyskinesias in PD – Frequency

    R. Doyle Maia, F. Cardoso, P. Caramelli (Vitória, Brazil)

    Objective: To evaluate the factors and possible mechanisms associated with anosognosia for LIDs in patients with PD using movie presentations and mirrored self-images. Background: Levodopa-induced…
  • 2017 International Congress

    The Personal Kinetigraph Fluctuator Score Identifies Motor Fluctuations in Parkinson’s disease

    E. Tan, M. Tagliati, E. Hogg, M. Horne (Los Angeles, CA, USA)

    Objective: To evaluate the Personal Kinetigraph (PKG) fluctuator score (FS) in detecting motor fluctuations in Parkinson's disease (PD) patients. Background: Fluctuations of response to levodopa,…
  • 2017 International Congress

    The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

    L. Sid-Otmane, S. Nuara, A. Hamadjida, N. Veyres, C. Rouillard, M. Panisset, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of metabotropic glutamate receptor 2 (mGluR2) activation on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset…
  • 2017 International Congress

    Design and personalisation of new upper-limb dynamic orthoses for dystonia and dyskinesia

    L. Garavaglia, M. Ferari, A. Lo Mauro, E. Pagliano, G. Baranello, B. Bassi, A. Aliverti, S. Pittaccio (Lecco, Italy)

    Objective: The study proposes a method to obtain anatomically- and functionally-personalised orthotics for the dynamic postural control of the upper limb. Background: The orthotic treatment…
  • 2017 International Congress

    Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.

    B. Schroeder, E. Thomas, T. Williams, S. Mahon, B. Mohamed (Cardiff, United Kingdom)

    Objective: To investigate if there is a significant relationship between weight loss in persons with Parkinson’s disease and side-effect incidence, and if so to what…
  • 2017 International Congress

    Tremor as the first symptom reported by Parkinson’s disease patients is a predictor of future motor subtype and levodopa-induced dyskinesia.

    A. Schumacher-Schuh, F. Drumond, J. Leal, M. Dotto, S. Machado, C. Rieder (Porto Alegre, Brazil)

    Objective: To better delineate risk profiles for the development of levodopa-induced dyskinesia is an important effort that can help understand this phenomenon and could impact…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley